Natacha Akshoomoff1, Sarah N Mattson2, Paul D Grossfeld3. 1. Department of Psychiatry, School of Medicine, University of California, San Diego, San Diego, California, USA. 2. Department of Psychology, San Diego State University, San Diego, California, USA. 3. Department of Pediatrics, School of Medicine, University of California, San Diego, San Diego, California, USA.
Abstract
PURPOSE: Jacobsen syndrome, also called the 11q terminal deletion disorder, is a contiguous gene disorder caused by the deletion of the end of the long arm of chromosome 11. Intellectual skills range from low average to severe/profound intellectual disability and usually correlate with deletion size. Comprehensive genotype/phenotype evaluations are limited, and little is known about specific behavioral characteristics associated with 11q terminal deletion disorder. METHODS: In this prospective study, 17 patients with 11q terminal deletion disorder underwent cognitive and behavioral assessments. Deletion sizes were determined by array comparative genomic hybridization. RESULTS: Deletion sizes ranged from 8.7 to 14.5 Mb across the patients. We found that 8 of 17 patients (47%) exhibited behavioral characteristics consistent with an autism spectrum disorder diagnosis. There was no correlation between deletion size and the presence of autism spectrum disorder, implicating at least one predisposing gene in the distal 8.7 Mb of 11q. The findings from three additional patients with autistic features and "atypical" distal 11q deletions led to the identification of an autism "critical region" in distal 11q containing four annotated genes including ARHGAP32 (also known as RICS), a gene encoding rho GTPase activating protein. CONCLUSION: Results from this study support early autism spectrum disorder screening for patients with 11q terminal deletion disorder and provide further molecular insights into the pathogenesis of autism spectrum disorder.
PURPOSE: Jacobsen syndrome, also called the 11q terminal deletion disorder, is a contiguous gene disorder caused by the deletion of the end of the long arm of chromosome 11. Intellectual skills range from low average to severe/profound intellectual disability and usually correlate with deletion size. Comprehensive genotype/phenotype evaluations are limited, and little is known about specific behavioral characteristics associated with 11q terminal deletion disorder. METHODS: In this prospective study, 17 patients with 11q terminal deletion disorder underwent cognitive and behavioral assessments. Deletion sizes were determined by array comparative genomic hybridization. RESULTS: Deletion sizes ranged from 8.7 to 14.5 Mb across the patients. We found that 8 of 17 patients (47%) exhibited behavioral characteristics consistent with an autism spectrum disorder diagnosis. There was no correlation between deletion size and the presence of autism spectrum disorder, implicating at least one predisposing gene in the distal 8.7 Mb of 11q. The findings from three additional patients with autistic features and "atypical" distal 11q deletions led to the identification of an autism "critical region" in distal 11q containing four annotated genes including ARHGAP32 (also known as RICS), a gene encoding rho GTPase activating protein. CONCLUSION: Results from this study support early autism spectrum disorder screening for patients with 11q terminal deletion disorder and provide further molecular insights into the pathogenesis of autism spectrum disorder.
Authors: Gene S Fisch; Paul Grossfeld; Rena Falk; Agatino Battaglia; Janey Youngblom; Richard Simensen Journal: Am J Med Genet C Semin Med Genet Date: 2010-11-15 Impact factor: 3.908
Authors: Murim Choi; Ute I Scholl; Peng Yue; Peyman Björklund; Bixiao Zhao; Carol Nelson-Williams; Weizhen Ji; Yoonsang Cho; Aniruddh Patel; Clara J Men; Elias Lolis; Max V Wisgerhof; David S Geller; Shrikant Mane; Per Hellman; Gunnar Westin; Göran Åkerström; Wenhui Wang; Tobias Carling; Richard P Lifton Journal: Science Date: 2011-02-11 Impact factor: 47.728
Authors: Remi Favier; Katayoun Jondeau; Patrice Boutard; Paul Grossfeld; Philippe Reinert; Christopher Jones; Francesco Bertoni; Elisabeth M Cramer Journal: Thromb Haemost Date: 2003-11 Impact factor: 5.249
Authors: Fares Zeidán-Chuliá; José Luiz Rybarczyk-Filho; Alla B Salmina; Ben-Hur Neves de Oliveira; Mami Noda; José Cláudio F Moreira Journal: Neuromolecular Med Date: 2013-03-02 Impact factor: 3.843
Authors: Maoqing Ye; Rabih Hamzeh; Amy Geddis; Nissi Varki; M Benjamin Perryman; Paul Grossfeld Journal: Am J Med Genet A Date: 2009-07 Impact factor: 2.802
Authors: Joanna Bernaciak; Krzysztof Szczałuba; Katarzyna Derwińska; Barbara Wiśniowiecka-Kowalnik; Ewa Bocian; Maria Małgorzata Sasiadek; Izabela Makowska; Paweł Stankiewicz; Robert Smigiel Journal: Am J Med Genet A Date: 2008-10-01 Impact factor: 2.802
Authors: Cydne A Perry; Marco Pravetoni; Jennifer A Teske; Carolina Aguado; Darin J Erickson; Juan F Medrano; Rafael Luján; Catherine M Kotz; Kevin Wickman Journal: Proc Natl Acad Sci U S A Date: 2008-06-03 Impact factor: 11.205
Authors: Mary Ella Pierpont; Martina Brueckner; Wendy K Chung; Vidu Garg; Ronald V Lacro; Amy L McGuire; Seema Mital; James R Priest; William T Pu; Amy Roberts; Stephanie M Ware; Bruce D Gelb; Mark W Russell Journal: Circulation Date: 2018-11-20 Impact factor: 29.690
Authors: Akiyoshi Uezu; Daniel J Kanak; Tyler W A Bradshaw; Erik J Soderblom; Christina M Catavero; Alain C Burette; Richard J Weinberg; Scott H Soderling Journal: Science Date: 2016-09-09 Impact factor: 47.728
Authors: Etzalli P Linares Chávez; Jaime Toral López; Juan M Valdés Miranda; Luz M González Huerta; Adrian Perez Cabrera; María Del Refugio Rivera Vega; Olga M Messina Baas; Sergio A Cuevas-Covarrubias Journal: Mol Syndromol Date: 2015-12-18
Authors: G Pathak; M J Agostino; K Bishara; W R Capell; J L Fisher; S Hegde; B A Ibrahim; K Pilarzyk; C Sabin; T Tuczkewycz; S Wilson; M P Kelly Journal: Mol Psychiatry Date: 2016-09-20 Impact factor: 15.992
Authors: Virgil A S H Dalm; Gertjan J A Driessen; Barbara H Barendregt; Petrus M van Hagen; Mirjam van der Burg Journal: J Clin Immunol Date: 2015-11-14 Impact factor: 8.317